Loading…
Collection numbers: ATCC 53103
Lacticaseibacillus rhamnosus GG (LGG) promotes early B lineage development and IgA production in the lamina propria in piglets
Lactobacillus rhamnosus GG (LGG) was the first strain belonging to the genus Lacticaseibacillus to be patented in 1989 thanks to its ability to survive and increase at gastric acid pH and in medium containing bile, and to adhere to enterocytes
The first sequencing took place in 2009 on Lactobacillus rhamnosus GG ATCC 53103.
Furthermore, LGG can produce a biofilm that can mechanically protect the mucosa and different soluble factors beneficial to the gut by enhancing intestinal crypt survival, diminishing apoptosis of the intestinal epithelium, and preserving cytoskeletal integrity.
Moreover, LGG, thanks to its lectin-like protein 1 and 2, inhibits some pathogens such as Salmonella species.
LGG can promote type 1 immune-responsiveness by reducing the expression of several inflammation markers on monocytes and increasing the production of interleukin-10, interleukin-12, and tumor necrosis factor-alfa in macrophages.
A large number of research data on Lactobacillus GG is the basis for using this probiotic for human health.
LGG has high capacity of adhesion to mucosal surfaces thank to his superficial exopolysaccharides and pili.
LGG adhesion to the mucosa is facilitate by the adhesive protein LGG-0186
LGG shows high immune activity
LGG can produce > 92 proteins in an acid pH milieu
Lactobacillus rhamnosus GG is safe at an early age and effective in treatment of allergic inflammation and food allergy
see also:
Culturelle TM
Normia Baby Probiotic
PROBIO-FIX INUM TM
Probiotics (living agents) & Salmonella Infection / Salmonellosis